AMPA receptor–mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: Insertion of AMPA receptor may play a role

Frontiers in Behavioral Neuroscience

Volumn 9, Issue JUNE, 2015, Pages

  Chen, Kuang Ti ^a   Tsai, Mang Hung ^a   Wu, Ching Hsiang ^b   Jou, Ming Jia ^c   Wei, I Hua ^a   Huang, Chih Chia ^a,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AMPA; Depression; mTOR; NMDA; Sarcosine

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; GLUR1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SARCOSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

EID: 84933047409     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2015.00162     Document Type: Article

References (54)

1. Banke, T. G., Bowie, D., Lee, H., Huganir, R. L., Schousboe, A., and Traynelis, S. F. (2000). Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J. Neurosci. 20, 89-102.
2. Campbell, S., and Macqueen, G. (2004). The role of the hippocampus in the pathophysiology of major depression. J. Psychiatry Neurosci. 29, 417-426.
3. Chen, N., and Napoli, J. L. (2008). All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARalpha. FASEB J. 22, 236-245. doi:10.1096/fj.07-8739com
4. Cleary, C., Linde, J. A., Hiscock, K. M., Hadas, I., Belmaker, R. H., Agam, G., et al. (2008). Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res. Bull. 76, 469-473. doi:10.1016/j.brainresbull.2008.03.005
5. Cryan, J. F., Page, M. E., and Lucki, I. (2005). Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl.) 182, 335-344. doi:10.1007/s00213-005-0093-5
6. Dahl, M., Bouchelouche, P., Kramer-Marek, G., Capala, J., Nordling, J., and Bouchelouche, K. (2011). Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol. Biol. Rep. 38, 4237-4243. doi:10.1007/s11033-010-0442-2
7. Depoortere, R., Dargazanli, G., Estenne-Bouhtou, G., Coste, A., Lanneau, C., Desvignes, C., et al. (2005). Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30, 1963-1985. doi:10.1038/sj.npp.1300772
8. Detke, M. J., Johnson, J., and Lucki, I. (1997). Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp. Clin. Psychopharmacol. 5, 107-112. doi:10.1037/1064-1297.5.2.107
9. Du, J., Machado-Vieira, R., Maeng, S., Martinowich, K., Manji, H. K., and Zarate, C. A. Jr. (2006). Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov. Today Ther. Strateg. 3, 519-526. doi:10.1016/j.ddstr.2006.11.012
10. Du, J., Suzuki, K., Wei, Y., Wang, Y., Blumenthal, R., Chen, Z., et al. (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders.Neuropsychopharmacology 32, 793-802. doi:10.1038/sj.npp.1301178
11. Dwyer, J. M., Lepack, A. E., and Duman, R. S. (2012). mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int. J. Neuropsychopharmacol. 15, 429-434. doi:10.1017/s1461145711001702
12. Encinas, J. M., Fernandez, A. P., Salas, E., Castro-Blanco, S., Munoz, P., Rodrigo, J., et al. (2004). Nitric oxide synthase and NADPH-diaphorase after acute hypobaric hypoxia in the rat caudate putamen. Exp. Neurol. 186, 33-45. doi:10.1016/j.expneurol.2003.09.024
13. Esteban, J. A., Shi, S. H., Wilson, C., Nuriya, M., Huganir, R. L., and Malinow, R. (2003). PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat. Neurosci. 6, 136-143. doi:10.1038/nn997
14. Fekadu, A., Wooderson, S. C., Markopoulo, K., Donaldson, C., Papadopoulos, A., and Cleare, A. J. (2009). What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J. Affect. Disord.116, 4-11. doi:10.1016/j.jad.2008.10.014
15. Hashimoto, K. (2011). The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry35, 1558-1568. doi:10.1016/j.pnpbp.2010.06.013
16. Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945. doi:10.1101/gad.1212704
17. Hoeffer, C. A., and Klann, E. (2010a). mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci.33, 67-75. doi:10.1016/j.tins.2009.11.003
18. Hoeffer, C. A., and Klann, E. (2010b). mTOR signaling: at the crossroads of plasticity, memory, and disease. Trends Neurosci.33, 67. doi:10.1016/j.tins.2009.11.003
19. Hogg, S. (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54, 21-30. doi:10.1016/0091-3057(95)02126-4
20. Huang, C. C., Wei, I. H., Huang, C. L., Chen, K. T., Tsai, M. H., Tsai, P., et al. (2013). Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol. Psychiatry 74, 734-741. doi:10.1016/j.biopsych.2013.02.020
21. Jernigan, C. S., Goswami, D. B., Austin, M. C., Iyo, A. H., Chandran, A., Stockmeier, C. A., et al. (2011). The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1774-1779. doi:10.1016/j.pnpbp.2011.05.010
22. Koike, H., and Chaki, S. (2014). Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav. Brain Res. 271, 111-115. doi:10.1016/j.bbr.2014.05.065
23. Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., et al. (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 7(Suppl. 1), S71-S80. doi:10.1038/sj.mp.4001021
24. Kugaya, A., and Sanacora, G. (2005). Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 10, 808-819.
25. Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964. doi:10.1126/science.1190287
26. Livingstone, M., Atas, E., Meller, A., and Sonenberg, N. (2010). Mechanisms governing the control of mRNA translation. Phys. Biol. 7, 021001. doi:10.1088/1478-3975/7/2/021001
27. Lu, W., Man, H., Ju, W., Trimble, W. S., Macdonald, J. F., and Wang, Y. T. (2001). Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 29, 243-254. doi:10.1016/S0896-6273(01)00194-5
28. Maeng, S., and Zarate, C. A. Jr. (2007). The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr. Psychiatry Rep. 9, 467-474. doi:10.1007/s11920-007-0063-1
29. Maeng, S., Zarate, C. A. Jr., Du, J., Schloesser, R. J., McCammon, J., Chen, G., et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349-352. doi:10.1016/j.biopsych.2007.05.028
30. Malkesman, O., Austin, D. R., Tragon, T., Wang, G., Rompala, G., Hamidi, A. B., et al. (2012). Acute d-serine treatment produces antidepressant-like effects in rodents. Int. J. Neuropsychopharmacol. 15, 1135-1148. doi:10.1017/s1461145711001386
31. Nestler, E. J., Barrot, M., Dileone, R. J., Eisch, A. J., Gold, S. J., and Monteggia, L. M. (2002). Neurobiology of depression.Neuron 34, 13-25. doi:10.1016/S0896-6273(02)00653-0
32. Palucha-Poniewiera, A., Szewczyk, B., and Pilc, A. (2014). Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology 82, 59-68. doi:10.1016/j.neuropharm.2014.03.001
33. Peng, X., Kim, J., Zhou, Z., Fink, D. J., and Mata, M. (2011). Neuronal Nogo-A regulates glutamate receptor subunit expression in hippocampal neurons. J. Neurochem. 119, 1183-1193. doi:10.1111/j.1471-4159.2011.07520.x
34. Porsolt, R. D., Bertin, A., and Jalfre, M. (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229, 327-336.
35. Reus, G. Z., Stringari, R. B., Ribeiro, K. F., Ferraro, A. K., Vitto, M. F., Cesconetto, P., et al. (2011). Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav. Brain Res. 221, 166-171. doi:10.1016/j.bbr.2011.02.024
36. Rizvi, S. J., Grima, E., Tan, M., Rotzinger, S., Lin, P., McIntyre, R. S., et al. (2014). Treatment-resistant depression in primary care across Canada. Can. J. Psychiatry 59, 349-357.
37. Rodgers, R. J., and Johnson, N. J. (1995). Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52, 297-303. doi:10.1016/0091-3057(95)00138-M
38. Schloesser, R. J., Huang, J., Klein, P. S., and Manji, H. K. (2008). Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33, 110-133. doi:10.1038/sj.npp.1301575
39. Shimizu-Sasamata, M., Kawasaki-Yatsugi, S., Okada, M., Sakamoto, S., Yatsugi, S., Togami, J., et al. (1996). YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J. Pharmacol. Exp. Ther. 276, 84-92.
40. Shor, B., Gibbons, J. J., Abraham, R. T., and Yu, K. (2009). Targeting mTOR globally in cancer: thinking beyond rapamycin.Cell Cycle 8, 3831-3837. doi:10.4161/cc.8.23.10070
41. Skolnick, P. (1999). Antidepressants for the new millennium. Eur. J. Pharmacol. 375, 31-40. doi:10.1016/S0014-2999(99)00330-1
42. Slipczuk, L., Bekinschtein, P., Katche, C., Cammarota, M., Izquierdo, I., and Medina, J. H. (2009). BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS ONE 4:e6007. doi:10.1371/journal.pone.0006007
43. Smith, K. E., Borden, L. A., Hartig, P. R., Branchek, T., and Weinshank, R. L. (1992). Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8, 927-935. doi:10.1016/0896-6273(92)90207-T
44. Smith, K. E., Gibson, E. S., and Dell'acqua, M. L. (2006). cAMP-dependent protein kinase postsynaptic localization regulated by NMDA receptor activation through translocation of an A-kinase anchoring protein scaffold protein. J. Neurosci. 26, 2391-2402. doi:10.1523/jneurosci.3092-05.2006
45. Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914. doi:10.1038/nature07762
46. Stewart, C. A., and Reid, I. C. (2002). Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission. Mol. Psychiatry 7(Suppl. 1), S15-S22. doi:10.1038/sj.mp.4001014
47. Tokita, K., Yamaji, T., and Hashimoto, K. (2012). Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol. Biochem. Behav. 100, 688-704. doi:10.1016/j.pbb.2011.04.016
48. Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., et al. (2006). Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354, 1243-1252. doi:10.1056/NEJMoa052964
49. Voleti, B., Navarria, A., Liu, R. J., Banasr, M., Li, N., Terwilliger, R., et al. (2013). Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 74, 742-749. doi:10.1016/j.biopsych.2013.04.025
50. Wang, Y., Barbaro, M. F., and Baraban, S. C. (2006). A role for the mTOR pathway in surface expression of AMPA receptors.Neurosci. Lett. 401, 35-39. doi:10.1016/j.neulet.2006.03.011
51. Zarate, C. A. Jr., Singh, J., and Manji, H. K. (2006a). Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 59, 1006-1020. doi:10.1016/j.biopsych.2005.10.021
52. Zarate, C. A. Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., et al. (2006b). A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864. doi:10.1001/archpsyc.63.8.856
53. Zarate, C. A. Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., et al. (2006c). A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 163, 153-155. doi:10.1176/appi.ajp.163.1.153
54. Zhang, H. X., Hyrc, K., and Thio, L. L. (2009). The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. J. Physiol. 587, 3207-3220. doi:10.1113/jphysiol.2009.168757